ArticleAntimicrobial agents and chemotherapy2016
Determining the Optimal Carbapenem MIC That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- AMRrounds: Metallo-β-lactamase-producingJAC-antimicrobial resistance · 2025Article
- Risk Factors and Outcomes of Patients Colonized with KPC and NDM Carbapenemase-Producing Enterobacterales.Antibiotics (Basel, Switzerland) · 2024Article
- Emergence of pandrug-resistant carbapenemase-producingFrontiers in cellular and infection microbiology · 2024Article
- Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model.Antibiotics (Basel, Switzerland) · 2023Article
- Fecal Carriage of Extended-Spectrum β-Lactamase-/AmpC-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Ertapenem Supplemented Selective Media as a New Strategy to Distinguish β-Lactam-Resistant Enterobacterales: Application to Clinical and Wastewater Samples.Antibiotics (Basel, Switzerland) · 2023Article
- Dissemination and characteristics of carbapenem-resistantFrontiers in microbiology · 2023Article
- Carbapenem antibiotic stress increases blaJournal of clinical laboratory analysis · 2022Article
- Epidemiological characteristics of carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii in a tertiary referral hospital in Korea.Osong public health and research perspectives · 2022Article
- The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.Frontiers in pharmacology · 2022Review
- Genomic Features Associated with the Degree of Phenotypic Resistance to Carbapenems in Carbapenem-Resistant Klebsiella pneumoniae.mSystems · 2021Article
- Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016-2018.Antimicrobial resistance and infection control · 2021Article
- Nanopore MinION Sequencing Reveals Possible Transfer ofFrontiers in microbiology · 2020Article
- Rapid Susceptibility Testing Methods.Clinics in laboratory medicine · 2019Review
- Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. A review of current challenge.Saudi medical journal · 2018Review
- Case Report of an Extensively Drug-ResistantOpen forum infectious diseases · 2018Article
- Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Is There a Carbapenem MIC Cutoff Value That Distinguishes Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem Non-Susceptible Pseudomonas and Acinetobacter Isolates?Infection control and hospital epidemiology · 2017Article
- Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae.Journal of clinical microbiology · 2017Article
- Use of Ancillary Carbapenemase Tests To Improve Specificity of Phenotypic Definitions for Carbapenemase-Producing Enterobacteriaceae.Journal of clinical microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenemase-producing (CP) Enterobacteriaceae are largely responsible for the rapid spread of carbapenem-resistant Enterobacteriaceae (CRE). Distinguishing CP-CRE from non-CP-CRE has important infection control implications. In a cohort of 198 CRE isolates, for isolates that remained susceptible or intermediate to some carbapenem antibiotics, an ertapenem MIC of 0.5 μg/ml and meropenem, imipenem, and doripenem MICs of 2 μg/ml were best able to distinguish CP-CRE from non-CP-CRE isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.